Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambr Nutri Sci Regulatory News (CNSL)

Share Price Information for Cambr Nutri Sci (CNSL)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.00 (0.00%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £4.40m
CNSL Live PriceLast checked at - London Stock Exchange

Intraday Cambr Nutri Sci Share Chart

Trading & Business Update

22 Apr 2026 07:00

RNS Number : 3731B
Cambridge Nutritional Sciences PLC
22 April 2026
 

Cambridge Nutritional Sciences plc

 

(the "Company" or "CNSL")

 

Trading & Business Update

 

Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, is pleased to announce an update on the Company's trading for the year ended 31 March 2026, ahead of the release of its audited final results in July 2026.

 

Highlights:

 

· Total Revenue expected to be £7.0m (2025: £8.3m)

· Gross profit margin of 67.8% (2025: 65.3%)

· Adjusted EBITDA** expected to show loss of £0.4m (2025: profit of £0.4m)

· Net cash balance of £2.6m (2025: £4.9m)

**Adjusted for exceptional items and share based payment charges

 

2026 financial performance:

 

Revenue was in line with market expectations after adjusting for reduced and delayed orders from the Middle East & Asia in the second half of the year. These were driven by a challenging and disrupted trading environment created by geopolitical instability and uncertainty, rather than a loss of local business partners. After adjusting for the impacted regions for the full year, underlying year on year revenue growth was approximately 11%.

 

Despite these revenue challenges, a continued focus on efficiencies and cost control across the business has resulted in a strong gross margin of 67.8% as well as an EBITDA loss of only £0.4m (vs £0.4m profit in 2025).

 

James Cooper, CEO, commented:

 

"I am pleased that underlying revenue adjusting for the economic disruption showed 11% growth; driven in particular by the UK and Indian markets, however we remain mindful of the potential for ongoing global uncertainties.

 

We continue to drive manufacturing efficiencies and are pleased to report a gross margin increase to 67.8%. This is a testament to all the hard work of my colleagues.

 

We are continuing to successfully progress our IVDR development programme following our heavy investment in capital equipment this year, which we believe will deliver significant product, cost and market position advantages to the Company for years to come.

 

I look forward to updating the market further at our results in July 2026."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

 

 

Contacts: 

 

Cambridge Nutritional Sciences plc

www.cnsplc.com

Carolyn Rand, Non-Executive Chair

investors@cnsplc.com

James Cooper, Chief Executive Officer

Ajay Patel, Chief Financial Officer

 

Cavendish Capital Markets Limited

 

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEFLFLQZLEBBK
12
Date   Source Headline
22nd Apr 20267:00 amRNSTrading & Business Update
31st Mar 20265:35 pmRNSHolding(s) in Company
31st Mar 20265:32 pmRNSHolding(s) in Company
19th Nov 20257:00 amRNSDirector/PDMR Shareholding
10th Nov 20257:00 amRNSHalf-year Report
4th Nov 20257:00 amRNSNotice of Results & Investor Presentation
25th Sep 20254:30 pmRNSResult of AGM
28th Aug 20257:00 amRNSNotice of AGM & Annual Report
21st Aug 20257:00 amRNSGrant of Options
19th Aug 20257:00 amRNSFinal Results
31st Jul 20257:00 amRNSNotice of Results & Investor Presentation
10th Jul 20257:00 amRNSDirectorate Change
2nd Jul 20257:00 amRNSHolding(s) in Company
27th May 20257:00 amRNSTrading Update
23rd May 20257:00 amRNSResolution on HSE Matter
8th Apr 20257:00 amRNSGrant of Options
1st Apr 20257:00 amRNSAppointment of Chief Executive Officer
21st Mar 202511:33 amRNSHolding(s) in Company
19th Mar 20257:00 amRNSOmega Diagnostics Summons Update
18th Mar 20252:48 pmRNSHolding(s) in Company
6th Feb 20257:00 amRNSDirector/PDMR Shareholding
30th Jan 20259:41 amRNSDirector/PDMR Shareholding
21st Jan 20254:03 pmRNSOmega Diagnostics court summons
16th Jan 20257:00 amRNSSettlement of DHSC Claim
7th Jan 20255:25 pmRNSHolding(s) in Company
7th Jan 20255:20 pmRNSHolding(s) in Company
4th Dec 20241:33 pmRNSHolding(s) in Company
4th Dec 20241:32 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSHalf-year Report
15th Nov 20249:24 amRNSNotice of Results and Investor Presentation
27th Sep 202411:20 amRNSResult of AGM
15th Aug 20243:44 pmRNSPosting of Annual Report and Notice of AGM
13th Aug 20247:00 amRNSDirectorate Change
5th Aug 202410:29 amRNSGrant of Options
25th Jul 20247:00 amRNSFinal Results
10th Jul 20247:00 amRNSNotice of Results
6th Jun 20244:26 pmRNSGrant of Options
24th May 20247:00 amRNSDirectorate Change
22nd Apr 20248:21 amRNSTrading Update and Directorate Change
3rd Apr 20247:00 amRNSQ2 2024 Industry Events Schedule
30th Jan 202412:50 pmRNSIssue of Equity and Total Voting Rights
29th Jan 20247:00 amRNSAppointment of Operations Director
22nd Jan 20247:00 amRNSScientific Educational Webinar and Industry Event
18th Dec 20233:51 pmRNSHolding(s) in Company
4th Dec 20237:00 amRNSScientific Educational Programme expanded
28th Nov 20233:56 pmRNSHolding(s) in Company
23rd Nov 20237:00 amRNSHalf-year Report
22nd Nov 202310:59 amRNSHolding(s) in Company
20th Nov 202311:09 amRNSHolding(s) in Company
17th Nov 202312:55 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.